FRAT1 Polyclonal Antibody, AbBy Fluor-405 Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-12434R-BF405-100uL |
| Product Name | FRAT1 Polyclonal Antibody, AbBy Fluor-405 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow |
| Specifications | |
| Conjugation | AbBy Fluor-405 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human FRAT1 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 10023 |
| Subcellular location | Cytoplasm |
| Synonyms | FRAT 1; frequently rearranged in advanced T cell lymphomas; Frequently rearranged in advanced T-cell lymphomas; GSK 3 binding protein FRAT1; proto oncogene FRAT1; FRAT1_HUMAN. |
| Background | FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is FRAT1 Polyclonal Antibody, AbBy Fluor-405 Conjugated (bs-12434R-BF405) validated for, and at what dilution?
bs-12434R-BF405 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-12434R-BF405 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise FRAT1 Polyclonal Antibody, AbBy Fluor-405 Conjugated (bs-12434R-BF405)?
KLH conjugated synthetic peptide derived from human FRAT1
What are the excitation and emission wavelengths of the AbBy Fluor-405 conjugate (bs-12434R-BF405)?
AbBy Fluor-405 on bs-12434R-BF405: excitation / emission 401nm/421nm.